NF-κB inhibition prevents apoptosis in cytokine-matured DCs treated with IFNβ and in LPS-matured DCs
| JSH-23, μM . | % Viability . | |
|---|---|---|
| TNF-α + IL-1β + IL-6 + PGE2 + IFNβ . | LPS . | |
| 0 | 44 ± 1 | 61 ± 3 |
| 0.1 | 54 ± 2 | 66 ± 1 |
| 1 | 71 ± 7 | 90 ± 1 |
| 10 | 95 ± 1 | 94 ± 1 |
| JSH-23, μM . | % Viability . | |
|---|---|---|
| TNF-α + IL-1β + IL-6 + PGE2 + IFNβ . | LPS . | |
| 0 | 44 ± 1 | 61 ± 3 |
| 0.1 | 54 ± 2 | 66 ± 1 |
| 1 | 71 ± 7 | 90 ± 1 |
| 10 | 95 ± 1 | 94 ± 1 |
CD11c+ DCs were pretreated with different concentrations of JSH-23 for 1 hour followed by treatment with the cytokine cocktail (TNF-α + IL-1β + IL-6 + PGE2) in the presence of IFNβ (500 IU/mL), or with LPS (100 ng/mL). A second dose of JSH-23 was added 24 hours later, and apoptosis was assessed 48 hours after the initiation of cultures by flow cytometry after annexin V/PI staining. Medium controls (no treatment) and cells treated with the cytokine cocktail in the absence of IFNβ averaged 90% to 95% viability.